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Cell lines and commodities: 
the Hagahai patent case 
In March 1995, the United States Government issued a patent on a human 
cell line for an indigenous Hagahai man from the rainforests of Papua New 
Guinea. Critics saw this as a 'new and dangerous' era in intellectual 
property while even defenders conceded there are serious dilemmas 
embracing ethics, the law and the media. 
By DAVID ROBIE 
GOROKA, Papua New Guinea (AP) — He's out there somewhere in the 
wild gorges of the Yuat River, hunting pig, harvesting yam, a young 
tribesman whose heart belongs to the jungle — but whose blood belongs 
to the United States Government. 
Or so says Patent N o 5,397,696. 
The story of the Hagahai tribesman, of how the United States patented the 
blood cells of one of Earth's most primitive citizens, could only be a tale 
from the bio-engineered Nineties, a time when the prehistoric can still 
come face to face with the futuristic, and the technology of tomorrow 
often outwits the society of today. C H A R L E S J. H A N L E Y (1996a) 
From the time the first European vessels reached the shores of continents 
long inhabited by indigenous people, European colonists adopted a terra 
nullius1 world view. Only very recently has the world begun to concede 
the inaccuracy of and racism behind this view. There is an almost 
desperate attempt by the descendants of colonisers to consign the terra 
nullius perspective to history, but recent developments in the area of 
human genetic research, engineering and human gene patents brings back 
haunting and painful memories to indigenous peoples of a legacy of 
European colonial domination. A R O H A T E P A R E A K E M E A D (1996a) 
ON 14 March 1995, the United States Government issued a patent on a human 
cell line, or culture, of aforeigner—an indigenous m a n from aremote rainforest 
area of Papua N e w Guinea. While global moves have been under way to protect 
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the knowledge and resources of indigenous people, the U S National Institutes 
of Health (NIH) were issued patent N o 5,397,696 by the Patent and Trademark 
Office (PTO), the first time that an indigenous person's cells have been 
patented. The act, described by some critics as a 'new and outrageous' era in 
intellectual property, has unleashed a major controversy embracing ethics, the 
law and the media (RAFI, 1996) over human genetic material. The Hagahai man 
was one out of a group of 24 whose cell lines were sampled in 1989, and in a 
similar case two Solomon Islanders were sampled in 1990 (Robie, 1995). 
The Hagahai, a tribe numbering less than 300 people, live in a remote part 
of the Western Schrader Mountains in Madang Province. In 1983, due to 
medical problems, the tribespeople initiated contact with the outside world by 
visiting Baptist missionaries who lived some distance away. The following 
year, they had their first sustained contact with outsiders when an evangelist set 
up camp at the nearby settlement of Yilu (Jenkins, 1987:413). Accompanying 
a Papua N e w Guinean Government census team the same year was an American 
medical anthropologist, Dr Carol Jenkins, who was affiliated with the P N G 
Institute of Medical Research (IMR). The team found the Hagahai to be 
suffering from endemic diseases with a low birth rate and high disease mortality 
(Los Angeles Times, 1987). The following year Jenkins began a decade-long 
research program funded by the U S National Geographic Society. 
Following the discovery of the Hagahai patent six months after it was 
registered, the Canadian-based non-government organisation Rural Advance-
ment Foundation International (RAFI) distributed an international press release 
on 4 October 1995, claiming the Hagahai man had 'ceased to own his genetic 
material' (RAFI, 1995). Pat Mooney, executive director of RAFI, was quoted 
as saying: 'This patent is another major step down the road to commodification 
of life. In the days of colonialism, researchers went after indigenous people's 
resources and studied their social organisations and customs. But now, in 
biocolonial times, they are going after the people themselves' (Ibid). 
RAFI and other N G O s argue that the World Health Organisation ( W H O ) 
should establish internationally-accepted medical ethics protocols covering the 
commercialisation or patenting of genetic material obtained from human beings 
(RAFI, 1996:1). N o such agreed ethical code exists at present. RAFI also 
believes the the Convention on Biological Diversity (CBD) should 'come to 
grips with its legal obligation' to conserve and protect human diversity and to 
establish binding procedures for the international exchange of human genetic 
resources. Finally, RAFI argues that it is concerned over the interest of U S Army 
and Navy researchers in HTLV-infected human cell lines from around the world 
with its implications for biological weapons research. 
But some leading scientists with links to the research, such as Temple 
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University anthropologist Dr Jonathan Friedlaender and law professor and 
ethicist Dr Henry Greely, have dismissed the controversy over the Hagahai 
patent as a 'tempest in a teapot' (Friedlaender, 1995). Former director of Pacific 
anthropology at the National Science Foundation, Friendlaender says the 
campaign 'reflects on the widespread distrust of the scientific technological 
enterprise and on the willingness of many to believe the worst of people with 
scientific knowledge' (Taubes, 1995). 
The issue has also involved allegations of harassment against the key 
scientist involved, Dr Carol Jenkins, initially by at least one newspaper in Papua 
N e w Guinea which eventually led to her seizure off an aircraft in Port Moresby 
by Foreign Affairs officials on her way to a conference abroad (Robie, 1996; 
Dorney, 1996). At least two scientists have accused the newspaper, The 
National, of waging a vindictive campaign against the P N G Institute of Medical 
Research in Goroka, the capital of Eastern Highlands province. Jenkins is one 
of the people named on the patent. 
Although the United States Government moved to register the patent in 19 
other countries — including Australia and N e w Zealand — under the interna-
tional Patent Cooperation Treaty, the controversy dogged its efforts. Finally, the 
U S retreated in late 1996 by ambiguously offering to abandon its rights in a 
decision welcomed by some critics as 'a step back from the aggressive patenting 
of life forms' (The National, 1996a) 
The legal, ethical and moral issues: 
The critical analysis: 
H u m a n genetic diversity (especially that of isolated indigenous communi-
ties) is a matter of increasing scientific, commercial and military interest. The 
flow of human genetic resources among military and civilian researchers across 
international borders is 'unmonitored and unrestricted' (RAFI, 1996) despite its 
value and significance. 
RAFI argues that the events surrounding the U S Government's patent ot a 
Hagahai man's cell line and intellectual property claims on citizens of the 
Solomon Islands show 'critical shortfalls in medical ethics, human rights 
provisions, and intergovernmental protocols with substantial economic and 
political implications' (Ibid). As discussed earlier, the N G O says the World 
Health Organisation should establish internationally accepted ethics protocols 
covering the commercialisation or patenting of genetic material obtained from 
human beings. 
Patented gene sequences and cell lines, stresses RAFI, generate enormous 
profits for the life industry: 'A single sequence can be worth US$1.5 billion a 
year, and more than a thousand patients on D N A sequences have been issued to 
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over 300 groups' (Thomas, 1996). While fewer cell lines have been patented, 
says RAFI, they are potentially equally valuable. Rights to asthma treatments 
derived from research on isolated populations' D N A have sold for US$70 
million (Shrine, 1995), while academic researchers have received 'gifts' from 
industry for more than US$12 million to further their collection of isolated 
peoples' tissues (RAFI, 1996:9). 
Many indigenous peoples argue Western science 'goes to great lengths to 
dehumanise the humanness, or life force, of human genes — hence terms such 
as specimens, materials, properties and collections are adopted as a means to 
ignore the essence of life contained within. It is contrary to indigenous tradition 
to "objectify" a gene or human organs as these are living and sacred' (Mead, 
1996). 
The scientific defence: 
Scientists and officials defending the Hagahai patent and the Human 
Genome Diversity Project (HGDP) say the critics are spreading misinforma-
tion, confusion and distrust. They argue that the Hagahai have a clear under-
standing of the concept of ownership and the research project only proceeded 
after the tribe speople's approval was given. They also say the likelihood of any 
commercial benefit from the discovery is 'very slight' (Alpers, 1996). They 
insist the Hagahai patent has nothing to do with the H G D P . 
The H G D P differs from the better known Human Genome Project, the huge 
endeavour that regularly makes headlines by finding links between diseases and 
genes: 'those inherited bits of D N A in our cells whose chemical code determine 
each body's characteristics' (Hanley, 1996b). One by one, 100,000 or so genes, 
collectively known as the human genome, are being blueprinted by the US$200 
million-a-year H G P . But everyone's genome is minutely different from every-
one else's, so scientists are developing only a composite of broadly shared 
D N A , using samples from a handful of North Americans and Europeans. 
The Diversity Project, on the other hand, would focus on the minute 
differences and reach cut to every corner of the globe. The plan, conceived by 
international geneticists, led by Stanford University's Luigi Luca Cavalli-
Sforza, would, say its defenders, coordinate independent gene-sampling projects 
already under way. According to its organisers, the project would take at least 
five years to collect blood or other D N A samples from perhaps 500 ethnic 
groups, with a focus on isolated populations. 
Geneticists hope to answer a key question of anthropology: Did modern 
humankind evolve in Africa and then migrate, or did it evolve on other 
continents, too? It is also hoped to discover clues to disease susceptibility or 
immunity (Ibid). 
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The Hagahai, or Melanesian, variant: 
According to writer Gary Taubes in Science magazine (1995), Papua New 
Guinea's Institute of Medical Research seems an 'unlikely target for such 
distrust'. There is indeed a patent, concedes Taubes, but not for a human. He 
describes how after a decade of research work with the Hagahai tribe, trying to 
identify and treat diseases that are reducing the small group to 'vanishing point', 
medical anthropologist Carol Jenkins and her I M R colleagues suddenly found 
themselves being accused of stealing Hagahai genes. The initial accusations 
came through a Papua N e w Guinean Foreign Affairs official, Dominic Sengi, 
who had formerly been a journalist and took to this affair with great zeal after 
seeing the 1995 U K Channel Four television documentary The Gene Hunters.2 
In a front-page story banner headlined, BATTLE O V E R B L O O D , Sengi reported: 
The blood of the recently discovered Hagahai people of Madang Prov-
ince is most likely to be the subject of an International Court of Justice 
hearing in The Hague, Netherlands. 
International lobbying has begun to have the Papua New Guinea Govern-
ment support the case which will challenge the United States' patent laws 
and ethics in medical research... 
RAFI is arguing that the patent applications amount to 'biopiracy ... that 
the patent represented the sort of profiteering from the biological inher-
itance of indigenous people that could become commonplace ...' (Sengi, 
1995) 
Then came the RAFI attack on 4 October 1995: 
INDIGENOUS PERSON F R O M P A P U A N E W GUINEA C L A I M E D IN US 
G O V E R N M E N T PATENT, blared an electronic press release, distributed around 
the world on the Internet. The press release also made disquieting allusions to 
scientific 'vampires'. Within the week, the chorus was taken up by local and 
international press. IS N O T H I N G SACRED? asked one headline, protesting the 
patent as a theft of human genetic material. Jenkins and her colleagues have been 
weathering a small storm ever since. 
Researchers had patented a virus-infected cell line from Hagahai blood and 
had actually agreed to give the Hagahai half the patent royalties. The accusations 
and press release came from a small Canadian-based group known as [RAFI] 
which says it is dedicated to the socially responsible development of 'technolo-
gies useful to rural societies'. By distributing the release via the Internet — a 
medium prized by scientists for its ability to disseminate information, but one 
proving equally adept at spreading misinformation — RAFI ensured a wide and i 
rapid airing. Consequences to date have been of the nuisance variety, but what 
is disturbing about the episode is that the charges have found a receptive 
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audience ... 
Institute staffers, [Jonathan] Friedlaender says, have been responsible for 
'the identification and [prevention] of a formerly widespread and lethal disease, 
known as pigbel, very important malarial research, ongoing and important 
public health education efforts in nutrition, [pneumonia], A I D S and ecological 
degradation'. The institute director, Michael Alpers, has won international 
awards in tropical medicine, and [Dr Carol] Jenkins, a MacArthur Foundation 
grantee, is considered an international authority on A I D S behavioural research 
and interventions (Taubes, 1995). 
But overall the Taubes article appeared rather one-sided, probably to 
balance the previous attacks. The article discussed how in the early 1990s, the 
I M R researchers, working with N I H virologist Carleton Gadjusek's group,' 
discovered that the Hagahai were infected with a variant of the human T cell 
leukaemia virus, or HLTV-I. The virus usually produced a severe form of 
leukaemia, but the Hagahai, or Melanesian, variant — previously unknown — 
is benign and thus interested researchers. Following then N I H guidelines, the 
researchers applied for a patent on an HTLV-infected cell line. 
While Jenkins argues that she discussed the idea of the patent with the 
Hagahai, who she says have a clear understanding of the concept of ownership, 
and only proceeded after securing their approval. 'They came to an agreement 
that the tribe would be the beneficiary of any royalties due the researchers,' 
writes Taubes (Ibid.). 
However, critics such as an authority on indigenous intellectual and cultural 
property rights, Aroha Te Pareake Mead, deputy convenor of N e w Zealand's 
Maori Congress, are scathingly sceptical. 'The Hagahai patent is immoral and 
unethical, but it is not unique — this is occurring all over the world,' says Mead. 
'Yesterday it was a Guaymi woman.4 Today it is a Hagahai man from Papua 
N e w Guinea. Tomorrow it will be a Solomon Islands man and other indigenous 
individuals" (Uni Tavur, 1996). In a communication with me, she remarked: 
Although many traditional cultures may not have words for "genetics" or 
"DNA", most have strong customs protecting the sanctity of hair, blood 
and saliva/mucus — the three sources of D N A most commonly tapped by 
Western researchers... 
The whole area of genetic research and genetic engineering is the ultimate 
dream of market- driven, reductionist-thinking scientists. N o w , human 
beings and the very life force and geneology contained within, have 
become products. Products to be owned, stored, traded and manipulated. 
I call it 'high-tech' slavery (Mead, 1996b). 
Mead developed this 'commodification' notion further in an unpublished paper 
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in which she was critical about assumptions over 'informed consent'. 
The absence of a robust methodology for gaining the consent of indigenous 
peoples is a grave concern. The potential to cause division within communities 
is a tragedy destined to happen. If consent is held as objective, then there must 
also be an understanding of dissent. As outsiders, who with [the scientists] 
approach? W h o will they consider to have a definitive vote? 
If fifty people say no, and twenty people say yes, is that informed consent? 
Can consent be reduced to an individual level when the very nature of 
genetic research implicates a wider group? What if a chief consents but 
members of the community oppose? That, of course, assumes that chiefs 
or current structures of tribal authority are equipped to deal with these 
matters (Mead, 1996a). 
But Mead stresses that indigenous peoples are not 'anti-science'. The UNESCO 
Bioethics Committee noted that while the 1993 Mataatua Declaration on 
Cultural and Intellectual Property Rights of Indigenous Peoples had demanded 
a halt to the H G D P , it had also called for 'involvement in scientific research by 
ensuring current scientific environmental research is strengthened by increas-
ing knowledge of indigenous communities and of customary environmental 
knowledge' (Ibid.) 
W h e n RAFI fuelled the controversy with its arguably provocative 4 
October 1995 press release, the N G O ' s head, Pat Mooney, was quoted as saying: 
'Once you allow patenting of any life form, you pretty much end up patenting 
all life forms. This was an especially outrageous example,' because it involved 
a small non-Western culture. As the press release put it, 'the United States 
Government has issued itself a patent on a foreign citizen. O n 14 March 1995, 
an indigenous man of the Hagahai people... ceased to own his genetic material' 
(RAH, 1995). 
According to one of RAFI's critics, Henry Greely, a law professor at 
Stanford University and chair of an ethics sub-committee for the H G D P , 'that's 
just wrong'. For a start, claims, Greely, 'the patent doesn't patent a person. It 
doesn't even patent human genetic material. It's the cell line, a viral preparation 
derived from the cell line, and three different bioassays to see whether people 
are infected by this virus. And the idea that the U S Government owns this person 
or his genetic material is absolute rubbish' (Taubes, 1995). 
Greely also circulated through the Internet criticisms by Dr Friedlaender 
who accused R A F I of pushing a 'conspiracy button'. H e claimed R A F I had been 
wrong on several points raised in the original media release. 
I got involved in this mess because, at the request of the Solomons Islands 
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Ambassador to the US, U N and Canada ... I called a couple of people at 
the NIH a year ago to find out about RAFI's claims that NIH was involved 
in patenting a Solomon Islander's genes. I got a satisfactory description 
of the situation, wrote the letter, had the NIH contact read and okay it as 
accurate, and then sent it to the Solomon Islands Ambassador. The 
important point was that the NIH had 'continued' the SI case, with the 
intention of abandoning it, and that that was their expectation for the P N G 
case, as well. 
Since that was what I was told, I didn't bother to check up further. As we 
all know, the P N G case was, contrary to m y letter, approved in March of 
[ 1995]. I only learned of that while visiting the [PNG] Institute of Medical 
research this past summer, after having visited the Solomon Islands. I 
expressed m y reservations to Dr Alpers about the patent, and received a 
reasonable reply (the entire issue of D N A patenting was still debatable, 
so in the absence of an international understanding, they were going 
ahead in order to make sure no one else claimed the viral variant; and that 
the Hagahai were going to be primary beneficiaries anyway). 
I didn't rush off and notify the SI Ambassador, or the SI Health Ministry 
officials I had spoken with earlier, because theirs was a different case, one 
that I understood was going to be dropped by the 'inventors'. In retro-
spect, this has been m y major sin of omission. And I have acknowledged 
as much in letters to the Ambassador and the Ministry of Health in the last 
two weeks. 
As soon as I saw RAFI's new charges, I called the NIH to establish the 
status of the SI case, and was assured that it had been entirely dropped — 
'withdrawn' is the official word (as opposed to its earlier status of 
'continued'). I still have no written proof of that, however (Friedlaender, 
1995). 
According to Friedlaender, Alpers and Jenkins were being besieged by local 
reaction in P a p u a N e w Guinea to the 'scurrilous' charges by R A F I , and that they 
were being unfairly targeted by The National because they had been critics of 
Rimbunan Hijau, the Malaysian logging group that owns the fastest-growing 
Papua N e w Guinean daily newspaper. 
The Institute of Medical Research is under a great deal of financial stress 
right now, and could go under. One newspaper in the country, owned by 
a Malaysian logging company that has obtained logging rights to enor-
mous stretches of the P N G rainforest, has been the primary trumpeter of 
RAFI's charges against the IMR. Since the I M R has been involved in 
attempts to preserve the rainforest, it makes sense the logging company's 
newspaper would like to discredit them. If you're looking for R E A L bio-
pirates ... I think the logging companies are the right folks to attack, not 
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the [PNG] Institute for Medical Research, the US Institutes of Health, or 
the Human Genome Diversity Project (Ibid.) 
On a more personal level, Friedlaender says an Australian university has refused 
to consider Jenkins for an appointment because she has become 'too controver-
sial'. Friedlaender adds: 'I find that nothing less than scandalous'. Also some 
reports of the degree of harassment experienced by Jenkins by journalists in 
Papua N e w Guinea appear to be sufficiently serious as to warrant complaints 
being filed with the P N G Media Council. 
Colleague Greely points out that while RAFI is right that the D N A of the 
Hagahai is part of the invention because it is present in the cell line. 'The donors 
involved can continue,' says Greely, 'obviously, to use their own D N A to run 
their bodies. They could also, if they chose, patent anything they wanted to 
patent that was an "invention" from their D N A ...,' except an H T L V cell line 
(Taubes, 1995). 
But whatever defenders of the patent may have been able to say about 
RAFI's original media release, it is far more difficult for them to find loopholes 
in the comprehensive 'New questions ...' document (RAFI, 1996). In fact, 
RAFI, making extensive use of the Freedom of Information Act in the US, has 
produced a damning case against the defenders and goes on to emphasise the 
links with other human tissue sample projects, such as in Colombia, and 
allegedly with military schemes. 
For example, defenders of the patent, both scientists and U S Government 
officials, have repeatedly argued that the Hagahai would receive 50 per cent of 
the royalties from any money made from the patent — and that an agreement 
exists with the Hagahai to this effect. Yet despite many oral, written and legal 
requests to the U S Government and other officials in the patent for copies of such 
a document to be made public, 'nobody involved with the patent had produced 
a copy, or any record of an oral agreement' (RAFI, 1996:5) 
RAFI raises several questions on this issue. First, and foremost, does such 
an agreement exist at all? If it does, what is this 50 per cent? Fifty per cent of 
NIH's NIH's proceeds? Fifty per cent of Dr Jenkins' portion of the royalties? 
Fifty per cent of the royalties after N I H and/or IMR's costs are subtracted? Are 
the Hagahai aware of the agreement? And, if so, are they aware that N I H has 
repeatedly said that it is unlikely that any money will result? (Ibid.) 
In April 1996, R A F I was told by N I H that it intended to withhold informa-
tion regarding the Solomon Islands cell lines and the Papua N e w Guinea patent 
on grounds of trade secrets — 'an indication that more intellectual property 
claims on indigenous people's cell lines are likely'. Following reports that blood 
collected in Colombia was being exchanged among institutions involved in 
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patenting in the US, RAFI also began an investigation into policy controls 
regarding NIH's sharing of human tissue samples. The arrest of Gajdusek (3) 
and publicity over N I H facilities at Fort Detrick also prompted RAFI to 
investigate the sharing of biomaterials with the U S military. 
RAFI's investigation quickly revealed that NIH not only has Colombian 
human tissue samples; but has an enormous number of them, including blood 
samples from at least 27 groups of 'healthy Colombian Indians from ... 
culturally distinct tribes distributed in 12 political departments (or states) and 
occupying markedly varying terrain' (Duenas-Barajas et al, 1993). Other 
research has revealed that the Atlanta-based Centres for Disease Control (CDC) 
. a U S Government institution which filed and then, under pressure, withdrew 
a patent application on a human cell line from the Guaymi people in Panama 
(RAFI, 1994), has additional Colombian communities (see details, RAFI. 
1996). 
The U S Navy, through medical research units in Jakarta, Indonesia, and 
Lima, Peru, also has its own program to collect blood samples for HTLV 
research. Following NIH's report on its research on the Hagahai cell lines, US 
Navy researchers travelled to Irian Jaya (West Papua), to collect their own 
H T L V samples from indigenous people (RAFI, 1996). They chose to sample 
165 members of the Ngalum people, an isolated group in the Jayawijaya 
Mountains along the Papua N e w Guinea/Indonesia border (AJTMH, 1993). 
In Peru, the U S Navy's research unit has also drawn blood samples for 
H T L V research. The samples were taken from '395 prostitutes from Callao, 
Peru (the port city of Lima), 72 prostitutes from Iquitos, Peru (another port city 
on the Amazon River) and 510 prenatal clinic patients from Lima' (JMV, 1992). 
RAFI has also documented that U S military-collected samples are almost 
certainly being shared with NIH and C D C researchers (RAFI, 1996:8). Follow-
ing 1972, the U S military partially vacated the Fort Detrick facility and NIH 
moved in. For Detrick is now shared by the National Cancer Institute (NCI), the 
National Institute of Neurological Disorders and Strokes (NINDS), and a 
medical section of the Defence Intelligence Agency. 
Conclusion: 
Procedures over the collection, handling and exchange of human tissue samples 
— especially across international borders — are conducted by an unacceptable 
ad hoc approach', RAFI argues. The transnational traffic in human tissue 
samples, especially those of indigenous people, appears to be growing sharply. 
The U S Government has patented the cell line of a Papua N e w Guinean 
indigenous person with no documentation of either his informed consent or 
approval of the Papua N e w Guinean Government. 
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However, the P N G Government implicitly gave its support to the project 
after researcher Carol Jenkins was summoned to the office of the then Foreign 
Affairs Secretary Gabriel Dusava who was later reported to have 'reached an 
understanding with emphasis on close cooperation between the Government 
and researchers in sensitive areas like human blood and viruses' (The National, 
1996b). The N I H has offered to transfer the patent rights to a trust benefiting the 
Hagahai, 'but biotechnology companies have shown no interest in the cell line' 
(The National, 1996a). Jenkins is reportedly against the transfer, citing the legal 
expense and US$6000 in fees payable to the U S Patent and Trademark Office 
(Ibid.). 
Although R A F I has found no evidence that U S military researchers have 
used foreign human cell lines for offensive biological warfare research, no 
policies or protocols prevent civilian medical researchers from sharing 
biomaterials with military researchers. And the U S does acknowledge that 
samples obtained from N I H are used in defensive programs. RAFI also believes 
that human tissues also 'flow from military researchers to NIH' (RAFI, 1996:8). 
Actions that can be taken by governments and non-government organisa-
tions to develop more effective controls on the patenting and exchange of human 
tissues include: seeking an investigation by the U N H u m a n Rights Commission 
into the H G D P , and the full disclosure of the project's files and membership; 
pressing for international protocols — such as legally binding commitments to 
prevent biomaterials collected for the purpose of medical research being 
accessible to military researchers in any way associated with chemical or 
biological warfare research; and demanding the requirement of prior informed 
consent from both the subjects of medical research and their communities or 
governments before any materials or information stemming from the research 
can be 'commodified'. 
Until these minimum requirements are established and being complied 
with, and an information program is under way, there should be no further 
collection or exchange of human tissue. 
Notes: 
1
 A Latin legal term meaning territory belonging to no one. As Aroha Mead notes, 
the general rule of the English common law system was that ownership could not be 
acquired by occupying land already occupied by another, hence settler governments 
evoked terra nullius in the new colonies thereby refusing to acknowledge existing 
indigenous inhabitants. See Mabo v State of Queensland, High Court of Australian 
Decision, F C 92/014, 3 June 1992. Mead says that she coopted the term to describe the 
mindset of colonisers. 
2
 Dominic Sengi initially began inquiries as part of a new Certificate in Investigative 
Journalism course at the University of Papua N e w Guinea (see 'The challenge of the 
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Hagahai blood saga', Uni Tavur, 4 August 1995, and T saw the need to open up debate: 
Sengi on the Hagahai saga', The Independent, 5 April 1996) but instead embarked on 
what lecturers described as a 'vendetta' against the individual scientists and the course 
disassociated itself from him. He was later implicated in the incident in which Dr Jenkins 
was hauled off an international flight and summoned before Foreign Affairs Secretary 
Gabriel Dusava. Sengi remarks: 'It pleases me to know that after my effort at bringing 
Carol to direct discussions with the Government, she is now seriously considering 
reassigning the rights back to the Hagahai people after I personally put to her that she 
has no legal evidence to go on publicly saying that rights have been secured for the 
Hagahai.' 
11n April 1996, Dr Carleton Gajdusek, head of the NIH laboratory that obtained the 
P N G patent, an 'inventor' in the Solomon Islands claim, and Nobel laureate, was 
arrested by the FBI and police in the U S on charges involving the sexual abuse of 
children who lived at his home. Over his career, Gajdusek had brought at least 54 
children from Micronesia and Papua New Guinea to the US, where they lived at the 
researcher's house and attended school at Gajdusek's expense (see 'NIH scientist 
charged with abusing teen; Nobel Laureate has brought dozens of boys to M d from 
overseas', Washington Post, 5 April 1996, pA-1.) 
4
 Under pressure from N G O s and indigenous people, the U S Government withdrew 
a 1993 patent application for cells from a Panamanian Guaymi woman (RAFI, 1996:2) 
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